secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2024-08-20T23:59:59+00:00
Accession:  0001493152-24-033220
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cocrystal Pharma to present at two investor conferences; outlines near-term clinical milestones
--------------------------------------------------------------------------------

- Expects to report topline results from influenza A Phase 2a challenge study (CC-42344) in 2024, final report in 2025.
- Expects to report topline results from Phase 1 multiple-ascending cohorts for oral norovirus/coronavirus protease inhibitor CDI-988 in late 2024 or early 2025.
- Management will present at Virtual Investor Summit Microcap Forum on Aug 20, 2024, and H.C. Wainwright Conference starting Sept 9, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000149315224033220/0001493152-24-033220-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000149315224033220/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-033220

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer